ADAM-Afatinib Diarrhea Assessment and Management

Boehringer Ingelheim

Status and phase

Completed

Phase 3

Conditions

Carcinoma, Non-Small-Cell Lung

Treatments

Drug: afatinib

Drug: loperamide

Study type

Interventional

Funder types

Industry

Identifiers

NCT01814553

1200.167

Details and patient eligibility

About

This is a non-randomized, open label, two-cohort, multi-institutional study to evaluate the use of diarrheal management tools intended to facilitate timely intervention and treatment modifications due to afatinib treatment-related diarrhea in patients with EGFR mutations-positive adenocarcinoma of the lung. Patients in Cohort 1 will follow diarrhea management. Patients in Cohort 2 will receive prophylactic loperamide starting the fist day of afatinib treatment.

Enrollment

40 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pathologically confirmed diagnosis of Stage IIIB or Stage IV adenocarcinoma of the lung, with EGFR mutations-positive status, who are not eligible to receive surgery or chemoradiotherapy. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology, and is a suitable candidate for EGFR-TKI monotherapy, in the opinion of the investigator.
Patients must have Epidermal Growth Factor Receptor (EGFR) mutation-positive status according to the institutional standard of care.
Patient received no more than one (1) prior chemotherapy for locally advanced or metastatic adenocarcinoma of the lung.
Male or female patients Age 18 years and older.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Adequate organ function, defined as all of the following:
- Left Ventricular Ejection Fraction (LVEF) of above 50% or within institution normal values
- Absolute neutrophil count (ANC) above 1500 / mm3.
- Platelet count above 75,000 / mm3.
- Estimated creatinine clearance more than 45ml / min.
- Total Bilirubin less than 1.5 times upper limit of (institutional/central) normal
- Aspartate amino transferase (AST) or alanine amino transferase (ALT) less than three times the upper limit of (institutional/central) normal (ULN) (if related to liver metastases less than five times ULN).
Recovered from any previous therapy related toxicity to Grade 0 or 1 at study entry
Able and willing to follow diarrhea management guidelines provided under this study and to complete Diarrhea Management Worksheet as instructed.

Exclusion criteria

Chemotherapy, biological therapy or investigational agents within four weeks prior to the start of study treatment.
Prior treatment with EGFR directed small molecules or antibodies.
Hormonal treatment within 2 weeks prior to start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted).
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study.
Known hypersensitivity to afatinib or the excipients of any of the trial drugs.
History or presence of clinically relevant cardiovascular abnormalities.
Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient¿s ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.
Previous or concomitant invasive malignancies at other sites.
Known pre-existing interstitial lung disease (ILD).
Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug.
Active hepatitis B infection, active hepatitis C infection and/or known HIV carrier, who are determined by the investigator as not a suitable candidate to receive EGFR-TKI treatment.
Patients with meningeal carcinomatosis. 16. Patients with brain or subdural metastases.